Yosuke Hirasawa, Takahiro Adachi, Takeshi Hashimoto, Wataru Fukuokaya, Yuhei Koike, Yuji Yata, Kazumasa Komura, Taizo Uchimoto, Takuya Tsujino, Kazuki Nishimura, Kiyoshi Takahara, Masanobu Saruta, Kazutoshi Fujita, Mamoru Hashimoto, Hirotsugu Uemura, Ryoichi Shiroki, Takashi Azuma, Takahiro Kimura, Yoshio Ohno
OBJECTIVES: Enfortumab vedotin (EV) is a novel antibody-drug conjugate approved for metastatic urothelial carcinoma (UC) refractory to prior treatment with immune checkpoint inhibitors (ICIs). However, the difference in efficacy of EV after each ICIs and prognostic factors are not well known. We aimed to compare the efficacy of EV in patients with metastatic UC who were treated with avelumab or pembrolizumab and to identify the prognostic factors. METHODS: The records of 100 patients with advanced metastatic UC who received EV after the administration of either avelumab or pembrolizumab were retrospectively collected from five academic hospitals in Japan...
April 9, 2024: Journal of Cancer Research and Clinical Oncology